Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

Amgen settles US cases for $762m

Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drug maker of marketing the anemia treatment Aranesp for unapproved uses.

The company pleaded guilty Tuesday to illegally introducing a misbranded drug into interstate commerce and will pay a $136 million fine and a $14 million forfeiture, according to the US Attorney’s Office for the Eastern District of New York.

Continue reading below

It also agreed to a $612 million civil settlement according to a law firm connected to the case.

But the US attorney’s office declined to comment on that because the civil settlement won’t be unsealed until a Wednesday court hearing.

Amgen said in an e-mail that if the court accepts the plea and sentence, it will immediately resolve civil and criminal matters.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com